Search results for "Bronchioles"

showing 2 items of 2 documents

Quantitative analysis of airway obstruction in lymphangioleiomyomatosis

2020

Lymphangioleiomyomatosis (LAM) is a rare, cystic lung disease with progressive pulmonary function loss caused by progressively proliferating LAM cells. The degree of airway obstruction has not been well investigated within the pathogenesis of LAM. Using a combination of ex vivo computed tomography (CT), microCT and histology, the site and nature of airway obstruction in LAM explant lungs was compared with matched control lungs (n=5 each). The total number of airways per generation, total airway counts, terminal bronchioles number and surface density were compared in LAM versus control. Ex vivo CT analysis demonstrated a reduced number of airways from generation 7 on (p<0.0001) in LAM compar…

Pulmonary and Respiratory MedicineLipopolysaccharidesPathologymedicine.medical_specialtyLung NeoplasmsPulmonary function testingPathogenesisOrphan Lung Diseases03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineMedicine and Health SciencesFLOW OBSTRUCTIONMedicineHumans030212 general & internal medicineLymphangioleiomyomatosisBronchiolesLungbusiness.industryHistologyOriginal ArticlesX-Ray MicrotomographyAirway obstructionrespiratory systemmedicine.disease133. Good healthrespiratory tract diseasesAirway Obstruction030228 respiratory systemPULMONARY LYMPHANGIOLEIOMYOMATOSISLymphangioleiomyomatosisHuman medicineAirwaybusinessQuantitative analysis (chemistry)Ex vivoCTThe European Respiratory Journal
researchProduct

Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma

2010

BACKGROUND: Airway inflammation in asthma involves both large and small airways, and the combination of inhaled corticosteroids (ICS) and long acting beta-2 agonists (LABA) is the mainstay of therapy. Available inhaled combinations differ in terms of drug delivery to the lung and the ability to reach small airways. Aim: To evaluate whether treatment with an extra-fine inhaled combination provides additional effects vs a nonextra-fine combination on airway function. METHODS: After a 1- to 4-week run-in period, patients with asthma were randomized to a double blind, double dummy, 12-week treatment with either extra-fine beclomethasone/formoterol (BDP/F) 400/24 microg daily or fluticasone prop…

AdultMaleChemistry PharmaceuticalBeclomethasoneBronchiPilot ProjectsSettore MED/10 - Malattie Dell'Apparato RespiratorioAsthmaFluticasone-Salmeterol Drug CombinationRespiratory Function TestsAndrostadienesDrug CombinationsDouble-Blind MethodEthanolaminesForced Expiratory VolumeFormoterol FumarateAdministration InhalationHumansAsthma Therapy small airwaysAlbuterolFemaleAnti-Asthmatic AgentsMetered Dose InhalersBronchioles
researchProduct